tiprankstipranks
Advertisement
Advertisement

ONC Stock Latest News

BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
Company AnnouncementsBeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
3d ago
8K
ONC
BeOne Medicines price target raised to $367 from $364 at Leerink
PremiumThe Fly
BeOne Medicines price target raised to $367 from $364 at Leerink
3d ago
ONC
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
PremiumThe Fly
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
5d ago
ONC
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
PremiumThe Fly
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
11d ago
ONC
BeOne Medicines price target raised to $409 from $405 at Barclays
PremiumThe Fly
BeOne Medicines price target raised to $409 from $405 at Barclays
11d ago
ONC
BeOne Medicines price target raised to $420 from $410 at Guggenheim
PremiumThe FlyBeOne Medicines price target raised to $420 from $410 at Guggenheim
11d ago
ONC
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
Premium
The Fly
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
11d ago
ONC
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
Premium
The Fly
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
11d ago
ONC
AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
PremiumThe Fly
AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
14d ago
AMD
BDX
BeOne Medicines initiated with an Overweight at Wells Fargo
PremiumThe Fly
BeOne Medicines initiated with an Overweight at Wells Fargo
14d ago
ONC
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
PremiumThe Fly
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
19d ago
ONC
BeOne Medicines price target lowered to $411 from $412 at Truist
PremiumThe Fly
BeOne Medicines price target lowered to $411 from $412 at Truist
1M ago
ONC
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
PremiumRatingsBuy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
2M ago
ONC
BeOne Medicines initiated with an Outperform at Wolfe Research
Premium
The Fly
BeOne Medicines initiated with an Outperform at Wolfe Research
2M ago
ONC
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
Premium
Company Announcements
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
2M ago
ONC
BeOne Medicines treatment of hepatocellular carcinoma granted orphan designation
PremiumThe Fly
BeOne Medicines treatment of hepatocellular carcinoma granted orphan designation
2M ago
ONC
BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
PremiumCompany Announcements
BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
2M ago
ONC
Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
PremiumCompany Announcements
Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
2M ago
ONC
BeOne Medicines downgraded to Hold from Buy at Jefferies
PremiumThe Fly
BeOne Medicines downgraded to Hold from Buy at Jefferies
2M ago
ONC
BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
PremiumCompany AnnouncementsBeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
2M ago
ONC
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
Premium
The Fly
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
3M ago
ONC
JAZZ
BeOne Medicines price target raised to $412 from $400 at Truist
Premium
The Fly
BeOne Medicines price target raised to $412 from $400 at Truist
3M ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >